AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01976325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ottawa Malaria Decision Aid
Description: The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
Study NCT01789476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
Study NCT01789476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered using same dosing algorithm as the active arm
Study NCT03362411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single 100 mg dose on Day 1 and Day 15
Study NCT04275830 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Baseline Surveys
Description: Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
Study NCT04275830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Surveys
Description: Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
Study NCT04275830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention.
Study NCT04275830 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Heart rate variability waitlist and Digital storytelling Control intervention
Description: Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
Study NCT00656669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib alone
Description: sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
Study NCT00656669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib plus paclitaxel
Description: sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
Study NCT00656669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin and cyclophosphamide
Description: doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
Study NCT02822729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution
Study NCT02822729 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DE-117 ophthalmic solution
Study NCT02822729 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Timolol ophthalmic solution
Study NCT03931902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubation with Endotracheal tube
Description: After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
Study NCT03931902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intubation with laryngeal mask airway
Description: After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
Study NCT02058264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000
Study NCT00679042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islets of Langerhans transplantation
Description: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant
Study NCT01302821 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon C 11 alpha-methyltryptophan
Description: The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
Study NCT03814954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
Study NCT03814954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
Study NCT02457325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgery with 2%Articaine first, then Surgery with 4% Articaine
Description: First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
Study NCT03638479 — intervention group
Intervention type: OTHER
Intervention: Data Capture
Description: This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
Study NCT02965027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Study NCT02085694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2
Study NCT02965027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01329562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet
Description: Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
Study NCT01329562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet matching Treximet for oral administration.
Study NCT00761735 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peginterferon alfa-2b
Description: In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
Study NCT00761735 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
Study NCT02229188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
Study NCT03115320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin
Description: Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
Study NCT03115320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home ovulation test
Description: The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
Study NCT03352544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training for 12 weeks (aerobic and resistance training trice a week)
Study NCT02229188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evolution
Description: Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
Study NCT02229188 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Words
Description: Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
Study NCT02457325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgery with 4%Articaine first, then Surgery with 2% Articaine
Description: First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
Study NCT01374308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NASVAC
Description: NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
Study NCT01374308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha 2b
Description: Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
Study NCT03385239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 678354
Description: ISIS 678354 solution for SC injection.
Study NCT03385239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ISIS 678354
Description: ISIS 678354 solution for SC injection.
Study NCT03385239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Normal Saline (0.9% NaCl).
Study NCT04361461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: 400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
Study NCT03194919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endre: a digital smoking cessation counsellor
Description: A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
Study NCT02689765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanins
Description: Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
Study NCT02689765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules is identically packaged.
Study NCT04132973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion for Skin Conditions
Description: Online guided self-help intervention derived from Compassion Focused Therapy (Gilbert, 2010).
Study NCT02044380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
Study NCT04361461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate + Azythromycin
Description: 400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
Study NCT02501096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
Study NCT02501096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
Study NCT04659785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
Study NCT04659785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
Study NCT01416168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McCorkle Model Intervention
Description: The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
Study NCT03200782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
Study NCT01129375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral
Study NCT03044834 — intervention group
Intervention type: OTHER
Intervention: PPB
Description: Global current care
Study NCT03368300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and biological exam
Description: The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma).
Study NCT04067050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A asphere
Description: Contact Lens
Study NCT04067050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Habitual spectacles
Study NCT01983267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cannabis
Description: use of cannabis oil or cigarets
Study NCT02691234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy and debridement
Study NCT02691234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: debridement and cleaning
Study NCT02691234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: debridement and cleaning
Study NCT01133730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active treatment
Description: US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
Study NCT01133730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: US-guided TFP block with 20ml of 5% dextrose solution
Study NCT00967330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10mg/kg iv every 2 weeks
Study NCT03200782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
Study NCT03173404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
Study NCT02468726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NER1008 enema
Description: NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
Study NCT02468726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet
Description: Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
Study NCT02254200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatmax group
Description: For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
Study NCT02254200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT group
Description: For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of \~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
Study NCT01177644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS 1.0
Study NCT03115619 — intervention group
Intervention type: DRUG
Intervention: Pirfenidone
Description: Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
Study NCT02400372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medihoney dressing
Description: to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
Study NCT02353715 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide
Study NCT02353715 — intervention group
Intervention type: DRUG
Intervention: Abiraterone acetate
Study NCT03994185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of WRAPSODY stent graft
Description: Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
Study NCT02353715 — intervention group
Intervention type: DRUG
Intervention: Sipuleucel-T
Study NCT02935530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s-LMWH
Description: 2125KU, subcutaneous injection of 5-10 days
Study NCT02935530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: 4250KU, subcutaneous injection of 5-10 days
Study NCT02935530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: 20mg, injection for 5-10 days